IR News

May 18, 2017Print(PDF/131KB)R&D

Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2017

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) announced today that a total of 12 presentations including clinical data for investigational anti-cancer agents napabucasin (BBI608), amcasertib (BBI503) and WT2725 will be presented at the poster session of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 to June 6, 2017.

Napabucasin: Study results, 7 presentations

Abstract
number
Title of poster presentationDate and Time,
Location
Study
number
Cancer
Type
9052 A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated non-squamous non-small cell lung cancer. June 3, 2017
8:00 AM-11:30 AM (local time),
Hall A
201 Study:
NCT01325441
Non-small cell lung cancer
3529 Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts). June 3, 2017
8:00 AM-11:30 AM (local time),
Hall A
246 Study:
NCT02024607
Colorectal cancer
4106 A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts). June 3, 2017
8:00 AM-11:30 AM (local time),
Hall A
118 Study:
NCT02231723
Pancreatic cancer
5548 A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated platinum resistant ovarian cancer. June 3, 2017
1:15 PM-4:45 PM (local time) ,
Hall A
201 Study:
NCT01325441
Ovarian Cancer
9553 A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma. June 3, 2017
1:15 PM-4:45 PM (local time) ,
Hall A
201 Study:
NCT01325441
Melanoma
1084 A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer. June 4, 2017
8:00 AM-11:30 AM (local time) ,
Hall A
201 Study:
NCT01325441
Breast cancer
4077 BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC). June 3, 2017
8:00 AM-11:30 AM (local time) ,
Hall A
BBI HCC 103
Study:
NCT02279719
Hepato-cellular carcinoma

Napabucasin: Study design, 2 presentations

Abstract
number
Title of poster presentationDate and Time,
Location
Study
number
Cancer
Type
TPS3619 CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC). June 3, 2017
8:00 AM-11:30 AM (local time) ,
Hall A
CanStem303C
Study:
NCT02753127
Colorectal cancer
TPS4148 CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC). June 3, 2017
8:00 AM-11:30 AM (local time) ,
Hall A
CanStem111P
Study:
NCT02993731
Pancreatic cancer

Amcasertib: Study results, 2 presentations

Abstract
number
Title of poster presentationDate and Time,
Location
Study numberCancer
Type
6032 A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor in advanced head and neck cancer. June 5, 2017
1:15 PM-4:45 PM (local time) ,
Hall A
101 Study:
NCT01781455
Head and Neck cancer
6036 A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma.  June 5, 2017
1:15 PM-4:45 PM (local time),
Hall A
101 Study:
NCT01781455
Adenoid Cystic Carcinoma

WT2725: Study results, 1 presentation

Abstract
number
Title of poster presentationDate and Time,
Location
Study
number
Cancer
Type
2066 Initial phase 1 study of WT2725 dosing emulsion in patients with advanced malignancies. June 5, 2017
1:15 PM-4:45 PM (local time),
Hall A
D8350004Study
:NCT01621542
Solid tumors, Hematologic malignancies

*The abstract is now available on the official website of ASCO. There is the link to applicable abstract on abstract number of each study.

(Reference)

【About napabucasin:BBI608】
Napabucasin is an investigational first-in-class anti-cancer agent created by Boston Biomedical, Inc., wholly-owned subsidiary of Sumitomo Dainippon Pharma. Napabucasin is an orally -administered small molecule agent with a novel mechanism of action designed to inhibit cancer stemness pathways by targeting STAT3.

【About amcasertib:BBI503】
Amcasertib is an investigational anti-cancer agent created by Boston Biomedical, Inc. Amcasertib is an orally-administered small molecule agent with a novel mechanism of action designed to inhibit cancer stemness pathways, including Nanog, by targeting stemness kinases.

【About WT2725】
WT2725 is an investigational therapeutic cancer peptide vaccine derived from Wilms' tumor gene 1 (WT1) protein. WT2725 is expected to treat various types of hematologic malignancies and solid tumors that express WT1, by inducing WT1-specific cytotoxic T-lymphocytes that attack WT1-expressing cancer cells.